Skip to main content
OpenTrials
Completed

NCT Number: NCT02622425

The Effect of PD01 on Cardiovascular Health and Microbial Environment

This randomized, placebo-controlled trial aims to determine the effects of daily administration of a carotenoid-producing Bacillus strain PD01 over a 6-week period on cardiovascular health biomarkers, microbiota composition and functioning and intestinal barrier function in overweight subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

MUMC+

Maastricht, Limburg, 6229HX, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Overweight men/women (BMI 25-35 kg/m2)
  • Healthy individuals
  • Age between 18 and 70 years
  • Fasting glucose < 7.0 mmol/L
  • Normal HbA1c (4.4 to 6.2%)

Exclusion criteria

  • Type 2 diabetes mellitus (defined as fasting plasma glucose ≥ 7.0 mmol/L);
  • History of (severe) cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol.
  • Abdominal surgery interfering with gastrointestinal function, upon judgment of the principle investigator)
  • Use of medication interfering with endpoints
  • Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine
  • Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
  • Use of antibiotics in the 90 days prior to the start of study
  • Known pregnancy, lactation
  • Abuse of products; alcohol (> 20 alcoholic consumptions per week) and drugs
  • Smoking
  • Blood donation within 3 months before study period
  • Plans to lose weight or following a hypocaloric diet during the study period;
  • Weight gain or loss > 3 kg in previous 3 months
  • High physical activity (>4.5 hours of running/week)
  • Hormone replacement therapy (women)
  • History of any side effects towards intake of pro- or prebiotic supplements of any kind
  • History of any side effects towards intake of carotenoids
  • Prohibited use of pro-, pre- or synbiotics during study period and from one month prior to start of study.
  • High intake of fruits and vegetables (more than the 75th percentile of dietary intake of fruits and vegetables)
  • Vegetarians/vegans

Treatment and study plan

Placebo

Dietary Supplement

maltodextrin

PD01

Dietary Supplement

Carotenoid-producing Bacillus strain PD01

Primary outcomes

  1. Effect on lipid peroxidation measured urinary F2-isoprostane excretion

    Time frame: 6 weeks

    The primary objective of this study is to evaluate the efficacy of PD01 on lipid peroxidation by measuring F2-isoprostane excretion in 24-hour urine, after 6 weeks of administration.

Secondary outcomes

  1. Effect on lipid peroxidation measured by blood concentration of F2-isoprostanes

    Time frame: 6 weeks

  2. Effect on lipid peroxidation measured by blood total antioxidant capacity

    Time frame: 6 weeks

  3. Effect on lipid peroxidation measured by blood MDA concentration

    Time frame: 6 weeks

  4. Effect on low-grade inflammation measured by blood concentration of TNFalfa

    Time frame: 6 weeks

  5. Effect on platelet aggregation measured by blood concentration of P-selectin

    Time frame: 6 weeks

  6. Effect on blood glucose concentrations measured by blood glucose concentration

    Time frame: 6 weeks

  7. Effect on blood lipid profile

    Time frame: 6 weeks

  8. Effect on blood pressure

    Time frame: 6 weeks

  9. Effect on body composition measured by BMI

    Time frame: 6 weeks

  10. Effect on body composition measured by waist-hip circumference (WHC)

    Time frame: 6 weeks

  11. The effect on fecal microbial community composition measured by fecal microbial community composition

    Time frame: 6 weeks

  12. The effect on fecal microbial community composition measured by fecal short chain fatty acids (SCFA)

    Time frame: 6 weeks

  13. Effect on gut barrier function measured by a sugar test

    Time frame: 6 weeks

  14. To assess the bioavailability of PD01 by measuring blood carotenoid concentration

    Time frame: 6 weeks

  15. Effect on digestive tolerance measured by GSRS questionnaire

    Time frame: 6 weeks

  16. Effect on digestive tolerance measured by Bristol Stool Chart

    Time frame: 6 weeks

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Registry information

Official study title

The Effect of the Carotenoid-producing Bacillus Strain PD01 on Cardiovascular Health and Microbial Environment

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Dec 4, 2015
Registry last updated
Dec 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.